Patent-Pending Status Obtained
Exciting news to share. Dermetel received patent-pending status on its innovative new treatment program, which is the first pharmaceutical of its kind to facilitate liver macrosome drug delivery. Please do sign up on the sign up sheet if you are interested in proceeding with the trial. Currently we have 187 sign ups and have a full support for a capacity of 2000 participants. We have applied for our patent of the treatment and expect to hit the South Korean market prior to November 2018. This makes Dermetel the single most comprehensive provider of innovative products and services for dermatologic diseases in the entire world, and marks the founding staff's first foray into the pharmaceutical industry. More information to come!